Phoremost logo

PhoreMost® is focused on bringing more effective and affordable targeted medicines to patients

PhoreMost® has developed a next-generation phenotypic screening platform called 'SITESEEKER®' to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.



Based on the Company’s proprietary PROTEINi® (Protein Interference) technology, PhoreMost has developed SITESEEKER; a platform that can systematically unmask hidden, or ”cryptic” druggable sites in the human genome and directly link them to useful therapeutic functions in a live-cell context. Using SITESEEKER, PhoreMost is building a pipeline of validated targets and drug discovery programs for further development, both internally and in partnership.